TGFB1 and triple-negative breast carcinoma: Notably, the synergistic activity between the TGF-β and EGFR signaling pathways, the FBXO3-mediated degradation of metastasis suppressors, and the integrin αvβ6–TGF-β–SOX4 axis represent potential therapeutic targets, especially in aggressive subtypes such as triple-negative breast cancer (TNBC).